Immunic, Inc. (NASDAQ:IMUX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET

Company Participants

Jessica Breu - VP, IR & Communications
Daniel Vitt - CEO
Glenn Whaley - CFO
Jason Tardio - COO

Conference Call Participants

Yasmeen Rahimi - Piper Sandler
Matt Kaplan - Ladenburg Thalmann
Tom Smith - Leerink Partners
Tyler Bussian - Brookline
Madison El-Saadi - B. Riley

Jessica Breu

Good morning, and welcome to Immunic's Second Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today.

Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer; Glenn Whaley, our Chief Financial Officer; as well as Jason Tardio, our newly appointed Chief Operating Officer and President. [Operator Instructions] This event is being recorded. [Operator Instructions]

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning. And such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.

Please note that these forward-looking statements reflect in Immunic's opinion only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.

I would now like to turn the call over to our CEO, Dr. Daniel Vitt, to begin the presentation. Daniel?

Daniel Vitt

Thank you, Jessica.

I would also like to welcome everybody to today's earnings call. Earlier this morning, we announced our financial results for the second quarter and six months ended June 30, 2024. During the call today, we will walk through our second quarter 2024 achievements and subsequent highlights, financial and operating results as well as our clinical development programs, including anticipated upcoming milestones. As Jessica noted, after the presentation, you will have the opportunity to ask questions.

Let's start with a review of our second quarter 2024 and subsequent highlights. In April, we hosted the multiple sclerosis IT Day in San Francisco, highlighting the latest developments in the MS landscape as well as our development program vidofludimus calcium.